Navigation Links
KV Pharmaceutical Company Completes Fiscal 2008 Filings With Securities and Exchange Commission
Date:6/25/2008

Company Files Fiscal Form 10-Q's for First Three Quarters of Fiscal 2008

and Form 10-K for Fiscal 2008 Ended March 31, 2008

Points to Positive Fiscal 2009 Outlook for Its Branded and Generic

Pharmaceutical Businesses

ST. LOUIS, June 25 /PRNewswire-FirstCall/ -- KV Pharmaceutical Company (NYSE: KVa/KVb), a fully integrated specialty pharmaceutical company that develops, manufactures, acquires and markets technology distinguished branded and generic/non-branded prescription pharmaceutical products, today announced that it has filed Form 10-Q's for the quarters ended June 30, 2007, September 30, 2007 and December 31, 2007, as well as a Form 10-K for its 2008 fiscal year ended March 31, 2008. The financial data included in these filings is consistent with previously reported preliminary financial results.

Marc S. Hermelin, Chairman of the Board and Chief Executive Officer stated, "With the filing of our fiscal 2008 financial reports, the Company is now up to date with its Securities and Exchange Commission filings. Fiscal 2008 was an extraordinary year for KV filled with many accomplishments by both our branded and generic businesses. Our Company continued to perform at record levels despite a difficult industry environment. We fully expect to continue our strong performance in fiscal 2009 and beyond as we execute on our branded and generic strategies and seek to capitalize on our valuable product pipeline."

Mr. Hermelin continued, "As previously reported, KV generated net revenue and net income increases of 36% and 52%, respectively, for fiscal 2008 compared to the prior year. In fiscal 2009 the Company expects to introduce 8-10 new products from Ther-Rx and ETHEX combined, which includes the anticipated approval of six ANDA's and one NDA. The anticipated new products, continued momentum from KV's generic Metoprolol Succinate Extended Release tablets, and expansion of the Company's branded women
'/>"/>

SOURCE KV Pharmaceutical Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
2. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
4. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
6. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
8. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
9. Par Pharmaceutical Files Form 10-K for 2006 -- Company to Hold First Analysts Meeting September 28, 2007
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Pharmaceutical Manufacturing Quality: Optimizing Your Internal Process for FDA Compliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... July 11, 2014 The Corn ... years to 2014 on the heels of fresh biofuel ... farmers to dedicate a larger share of their farmland ... specifically, the regulations required the mixing of 5.0% renewable ... production in the United States created a key export ...
(Date:7/11/2014)... Ticket Down is a reliable source ... Amphitheatre in Wheatland, CA. In the Sacramento California ... the Sleep Train Amphitheatre can do for music fans. The ... the course of its existence and can seat 18,500 fans ... Wheatland (Sacramento metro area) will host the “That’s My Kind ...
(Date:7/11/2014)... Pigments are insoluble colorants, which usually consist of ... coating, opacity, and coloring. These are water and oil ... substances such as paper, paints, plastics, and concrete. Binders ... impart color to the substance. Some examples of pigments ... , The coloring action of pigments is due to ...
(Date:7/11/2014)... York, NY (PRWEB) July 11, 2014 ... dramatic increase in men seeking cosmetic surgery and hair ... year. With such an expansive range of medical tourism ... exceptional plastic surgery costs and achieve the ... to be renowned as the top name in the ...
Breaking Medicine News(10 mins):Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 2Health News:Luke Bryan Tickets Sleep Train Amphitheatre in Wheatland, CA (Sacramento): Ticket Down has Slashed Ticket Prices on Luke Bryan in Wheatland at Sleep Train 3Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 2Health News:Americas Pigments Market Worth 1,099 Thousand MT by 2018 - New Report by MicroMarket Monitor 3Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 2Health News:VisitandCare.com Reports Increase in Cosmetic and Hair Transplant Procedures for Men 3
... a 47-year-old man who had worked for a Hindustan Lever ... who had also been exposed to toxic mercury, to the ... than 500 protestors, who said he had been slowly poisoned ... an autopsy to assess the possibility of mercury-induced damage. ...
... new study examined the connection between Baltimore City’s needle ... ,Individuals who enter treatment programs for drug addiction were ... Baltimore City needle exchange programs. ,The ... of Public Health highlights the need for treatment facilities ...
... always the result of a subtle marriage between a ... an appropriate excipient// (a neutral substance in which the ... absorbed by the body). Thus the necessary tablet, capsule ... biodegradable materials were used instead of these neutral excipients? ...
... multiple positive social outcomes,// research conducted in rural ... of the Journal of Acquired Immune Deficiency Syndromes ... appear to lead to stigmatisation or an increase ... increase in the incidence of domestic violence against ...
... transition service has been instituted by the NHS trust to ... ,‘Minding the Gap’, a document enabled by ... regular service for 16- to 18-year-olds, in Durham and Darlington. ... out to the teenagers suffering health problems across six primary ...
... Complementary //and Alternative Medicine (NCCAM) at the National Institutes ... better, especially about alternative therapies they are trying out ... ,This is the outcome of a survey conducted ... 1600 patients, and their doctors. ,It ...
Cached Medicine News:Health News:Ex-workers Ask HLL to Accept Liability for Mercury Deaths 2Health News:Drug Treatment Seekers Likely to Use Needle Exchange 2Health News:New Generation - Medicinal Products 2Health News:New Generation - Medicinal Products 3Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 2Health News:HIV Home-based Care Produces Positive Outcomes in Uganda 3Health News:Elderly Patients Usually Keep Mum About Use of Alternative Medicine , Reveals Survey 2
(Date:1/15/2014)... DUBLIN , January 15, 2014 Shire plc ... waived the Office of Fair Trading (OFT) approval condition to the ... Incorporated (NASDAQ: VPHM).   As a result of the ... Shire expects to complete the tender offer on January 24, 2014 ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
Breaking Medicine Technology:Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Superbugs No Longer Ride In Rescue Vehicles 2
... , , SAN DIEGO, Aug. 27 ... Company has begun a clinical trial intended to secure U.S. regulatory approval ... determine the need for a repeat prostate biopsy. , ... studies and our European commercial experience, we believe that our PROGENSA PCA3 ...
... , , , ... an 82-year old New Orleans resident with severe aortic stenosis successfully had ... as angioplasty, a far cry from the traditional open heart procedure. Patients ... now have a potential new research option available regionally only through The ...
Cached Medicine Technology:Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 2Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 3Gen-Probe Begins U.S. Clinical Study of PROGENSA(R) PCA3 Assay, New Molecular Test to Help Assess Prostate Cancer Risk 4Ochsner Replaces Heart Valve Without Open Heart Surgery 2
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... program offers state-of-the-art quality in an instrument ... and durability. Low profile cutting tips allow ... Series I instruments are available in just ... angle required for large and small joint ...
... The WideBiter Punch series facilitates fast ... recreating a smooth, anatomically shaped meniscal rim. ... low profile to access even the tightest ... Arthrex California, Inc., 20 years of engineering ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
Medicine Products: